Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keywan Mortezaee

Showing results (21-30 of 142) with videos related to

Pageof 15
Sort By:
International Journal of Biological Macromolecules|April 28, 2025
T-cell immunoglobulin and ITIM domain as a target in combo anti-PD-(L)1 cancer therapyKeywan Mortezaee
Cytokine|March 28, 2024
FOXP3 (in)stability and cancer immunotherapyKeywan Mortezaee
Medical Oncology (Northwood, London, England)|February 11, 2024
Selective targeting or reprogramming of intra-tumoral TregsKeywan Mortezaee
Cancer Medicine|March 18, 2022
Checkpoint inhibitor/interleukin-based combination therapy of cancerKeywan Mortezaee, Jamal Majidpoor
Journal of Cellular and Molecular Medicine|January 10, 2023
Transforming growth factor-β signalling in tumour resistance to the anti-PD-(L)1 therapy: UpdatedKeywan Mortezaee, Jamal Majidpoor
Medical Oncology (Northwood, London, England)|June 18, 2022
NK and cells with NK-like activities in cancer immunotherapy-clinical perspectivesKeywan Mortezaee, Jamal Majidpoor
Life Sciences|December 28, 2023
Modifying CAR-T cells with anti-checkpoints in cancer immunotherapy: A focus on anti PD-1/PD-L1 antibodiesSajad Najafi, Keywan Mortezaee
Journal of Cellular Physiology|October 13, 2017
Melatonin application in targeting oxidative-induced liver injuries: A reviewKeywan Mortezaee, Neda Khanlarkhani
Medical Oncology (Northwood, London, England)|March 25, 2023
The impact of hypoxia on extracellular vesicle secretome profile of cancerKeywan Mortezaee, Jamal Majidpoor
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 17, 2026
Retraction notice to "Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications" [Biomedicine & Pharmacotherapy 145 (2022) 112419]Jamal Majidpoor, Keywan Mortezaee
Pageof 15

Showing results (21-30 of 142) with videos related to

Sort By:
Pageof 15
International Journal of Biological Macromolecules|April 28, 2025
T-cell immunoglobulin and ITIM domain as a target in combo anti-PD-(L)1 cancer therapyKeywan Mortezaee
Cytokine|March 28, 2024
FOXP3 (in)stability and cancer immunotherapyKeywan Mortezaee
Medical Oncology (Northwood, London, England)|February 11, 2024
Selective targeting or reprogramming of intra-tumoral TregsKeywan Mortezaee
Cancer Medicine|March 18, 2022
Checkpoint inhibitor/interleukin-based combination therapy of cancerKeywan Mortezaee, Jamal Majidpoor
Journal of Cellular and Molecular Medicine|January 10, 2023
Transforming growth factor-β signalling in tumour resistance to the anti-PD-(L)1 therapy: UpdatedKeywan Mortezaee, Jamal Majidpoor
Medical Oncology (Northwood, London, England)|June 18, 2022
NK and cells with NK-like activities in cancer immunotherapy-clinical perspectivesKeywan Mortezaee, Jamal Majidpoor
Life Sciences|December 28, 2023
Modifying CAR-T cells with anti-checkpoints in cancer immunotherapy: A focus on anti PD-1/PD-L1 antibodiesSajad Najafi, Keywan Mortezaee
Journal of Cellular Physiology|October 13, 2017
Melatonin application in targeting oxidative-induced liver injuries: A reviewKeywan Mortezaee, Neda Khanlarkhani
Medical Oncology (Northwood, London, England)|March 25, 2023
The impact of hypoxia on extracellular vesicle secretome profile of cancerKeywan Mortezaee, Jamal Majidpoor
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 17, 2026
Retraction notice to "Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications" [Biomedicine & Pharmacotherapy 145 (2022) 112419]Jamal Majidpoor, Keywan Mortezaee
Pageof 15